$PMC (PharMerica Corporation)

$PMC {{ '2016-04-04T12:25:25+0000' | timeago}} • Announcement

$PMC said it provided an update on its ongoing litigation against AmerisourceBergen Drug Corp., or ABDC, its former wholesale supplier of pharmaceutical products. On April 1, the Jefferson County, Kentucky Circuit Court handed down partial summary judgment ruling that $PMC honor outstanding invoices from ABDC for about $48.5MM.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$REGN {{ '2017-12-18T12:38:12+0000' | timeago}} • Announcement

$REGN and ISA Pharmaceuticals announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. $REGN and ISA will jointly conduct trials of treatment in cervical cancer and head-and-neck cancer.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$PMC {{ '2017-12-07T18:06:23+0000' | timeago}} • Announcement

$PMC announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of $WBA as a minority investor.

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$CVS {{ '2017-12-04T21:29:13+0000' | timeago}} • Announcement

$CVS has agreed to acquire $AET for appox. $207 per share or approx. $69Bil. Including the assumption of $AET debt, the total value of the deal is $77Bil. The transaction is expected to close in the second half of 2018.

$LHCG {{ '2017-12-04T19:56:36+0000' | timeago}} • Announcement

$LHCG and Erlanger Health System have finalized a new JV to enhance home health and community-based services in Chattanooga and southeast Tennessee. The JV includes a Chattanooga facility, which will operate as Erlanger ContinuCare Home Health. $LHCG expects annualized revenue from this JV of approx. $7MM and no material effect to 2017 diluted EPS.

$REGN {{ '2017-11-29T15:11:06+0000' | timeago}} • Announcement

Pharma firm $REGN has joined hands with Decibel Therapeutics, a provider of hearing therapies, to develop new treatments for hearing problems. As per the terms of the deal, Regeneron will provide Decibel with access to its proprietary technologies, besides participating in the latter’s research programs through R&D funding and an equity investment.

$REGN {{ '2017-11-27T12:48:48+0000' | timeago}} • Announcement

$REGN said results from two Phase 2 studies that added the angiopoietin2 to EYLEA injection did not provide sufficient differentiation to warrant Phase 3 development. EYLEA results were consistent with the findings in previous clinical studies.

$LHCG {{ '2017-11-16T14:14:41+0000' | timeago}} • Announcement

$LHCG-$AFAM merger will create a nationwide provider of in-home healthcare services. The combined company will have 781 locations in 36 states with more than 31,000 employees and revenue of $1.8Bil and adjusted EBITDA of approx. $145MM for the trailing 12-month period ended Sept. 30, 2017.

$LHCG {{ '2017-11-16T14:13:01+0000' | timeago}} • Announcement

$LHCG and $AFAM have agreed to combine in an all-stock merger of equals transaction. Almost Family shareholders will receive 0.9150 shares of LHC Group for each existing Almost Family share. Upon closing of the transaction, LHC Group shareholders will own 58.5% and Almost Family shareholders will own 41.5% of the combined company.

$REGN {{ '2017-11-08T20:41:09+0000' | timeago}} • Webcast

$REGN said Sanofi reimbursement of its commercialization-related expenses, was $90MM for 3Q17. "We are tightening and lowering our FY17 guidance of Sanofi reimbursement of Regeneron commercialization-related expenses to $350-375MM from our previous guidance range of $370-400MM," the company said.

$REGN {{ '2017-11-08T15:12:08+0000' | timeago}} • Infographic

$REGN Regeneron Pharmaceuticals, Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$CVS {{ '2017-11-08T12:39:44+0000' | timeago}} • Webcast

For 4Q17, $CVS expects a negative free cash flow, as the company plans to settle the CMS payable associated with the 2016 plan year. Based on this the company maintains its FY17 guidance and continues to expect to produce free cash of between $6-6.4Bil

Recent Transcripts

RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
PRSC (Providence Service Corp.)
Wednesday, November 8 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
LHCG (LHC Group, Inc.)
Monday, November 6 2017 - 4:00pm
CVS (CVS Health Corporation)
Monday, November 6 2017 - 1:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
USPH (US Physical Therapy Inc.)
Thursday, November 2 2017 - 2:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
CHE (Chemed Corp.)
Friday, October 27 2017 - 2:00pm
PETS (PetMed Express, Inc.)
Monday, October 23 2017 - 12:30pm
RAD (Rite Aid Corporation)
Thursday, September 28 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 8:30pm
PRSC (Providence Service Corp.)
Wednesday, August 9 2017 - 12:00pm
CNCE (Concert Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 12:30pm
CVS (CVS Health Corporation)
Tuesday, August 8 2017 - 12:30pm

AlphaGraphics you may like